Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 3/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.36 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.36 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.36 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848673 | 0.89 | CTSK (0.38) | CASP3TACR1MCOLN2MCOLN1TAOK1 | |
| SCHEMBL5848731 | 0.85 | TAOK1 (0.43) | CASP3POLBTAOK1TAOK3HDAC1 | |
| SCHEMBL6867039 | 0.85 | TAOK1 (0.43) | CASP3POLBTAOK1TAOK3HDAC1 | |
| SCHEMBL5850513 | 0.85 | TAOK1 (0.43) | CASP3POLBTAOK1TAOK3HDAC1 | |
| SCHEMBL5848743 | 0.85 | TAOK1 (0.43) | CASP3POLBTAOK1TAOK3HDAC1 | |
| SCHEMBL5848493 | 0.85 | TAOK1 (0.43) | CASP3POLBTAOK1TAOK3HDAC1 | |
| SCHEMBL5849232 | 0.85 | PSMB5 (0.48) | CAPN1BRS3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL5848739 | 0.84 | HTR1A (0.39) | MCOLN2MCOLN1TAOK1TAOK3 | |
| SCHEMBL5848529 | 0.83 | TAOK1 (0.42) | CAPN1MCOLN2MCOLN1TAOK1TAOK3 | |
| SCHEMBL5850540 | 0.83 | TAOK1 (0.42) | CAPN1MCOLN2MCOLN1TAOK1TAOK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7008938-B2 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | NOKIA CORPORATION (FI) | 2006-03-07 | — | — | US | claimed |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | claimed |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | NOKIA CORPORATION (FI) | 2003-08-28 | — | — | US | claimed |
| EP-1254898-A1 | BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-7008938-B2 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | NOKIA CORPORATION (FI) | 2006-03-07 | — | — | US | disclosed |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-6809092-B2 | 1,3,4,5-TETRAHYDRO-2H-2-BENZAZEPIN-2-YL DERIVATIVES; CYSTEINE PROTEASE INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | NOKIA CORPORATION (FI) | 2003-08-28 | — | — | US | disclosed |
| EP-1254898-A1 | BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | BACH1, BACE1, CMA1 | CAPN1 242/4885BRS3 832/4885CASP3 233/4885 |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | BACE1, BACE2, CBS | CAPN1 402/4885BRS3 954/4885CASP3 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.